Patent ID: 8758802

Claim:
A method of inhibiting or reversing in situ the progression of cataract formation in an eye comprising contacting the crystalline lens in situ in the eye with an effective cataract-inhibiting amount of an ophthalmic composition comprising at least one β L -crystallin electrostatic interaction inhibitor, wherein the β L -crystallin electrostatic interaction inhibitor is an organic or inorganic salt selected from NH 4 Cl, CaCl 2 , sodium acetate, potassium acetate, ammonium acetate, sodium citrate, potassium citrate, ammonium citrate, sodium sulphate, potassium sulphate, ammonium sulphate, calcium acetate, ethylammonium nitrate, sodium formate, sodium ascorbate, magnesium gluconate, sodium gluconate, tromethamine hydrochloride, sodium succinate, and combinations thereof.